The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

opsens.com

Founded Year

2003

Stage

IPO | IPO

Market Cap

0.20B

About Opsens

Opsens makes fiber optic sensors. Its optical-based pressure guidewire, called OptoWire, aims to improve results for patients with coronary artery disease.

Opsens Headquarter Location

750, Boul. du Parc Technologique

Quebec, Quebec, G1P 4S3,

Canada

418-781-0333

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Opsens

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Opsens is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

3,088 items

Companies that have been granted at least 1 510(k) by the FDA since 2014. Companies tagged as #FDA510(K)

Opsens Patents

Opsens has filed 20 patents.

The 3 most popular patent topics include:

  • Catheters
  • Implants (medicine)
  • Interventional radiology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/17/2019

7/27/2021

Graphical user interface elements, Graphical user interfaces, Graphical control elements, Graphical user interface testing, User interfaces

Grant

Application Date

5/17/2019

Grant Date

7/27/2021

Title

Related Topics

Graphical user interface elements, Graphical user interfaces, Graphical control elements, Graphical user interface testing, User interfaces

Status

Grant

Latest Opsens News

07:00 EDT OPSENS ANNOUNCES HEALTH CANADA APPROVAL FOR ITS NEW TAVR GUIDEWIRE

Apr 26, 2022

News provided by Share this article Share this article QUEBEC CITY, April 26, 2022 /CNW Telbec/ - OpSens Inc. ("OpSens" or the "Company") (TSX: OPS ) (OTCQX: OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that it has received Health Canada approval for the SavvyWire™, its new guidewire for transcatheter aortic valve replacement procedures, or TAVR. "For OpSens, Health Canada's approval is an important milestone on the path to the commercialization of the SavvyWire, which was specifically designed and developed to facilitate the procedure for transcatheter aortic valve replacement," commented Louis Laflamme, President and CEO of OpSens. "The introduction of a next-generation guidewire with the ability to deliver a prosthetic valve and designed for rapid-pacing while allowing continuous measurement of hemodynamic pressure during the procedure is considered a significant benefit as the number of TAVR procedures is rapidly growing. We are prepared to initiate a phased commercialization in Canada over the coming months with a full launch expected toward the back half of 2022," concluded Mr. Laflamme. The SavvyWire, a third-generation, intelligent, pre-shaped, structural guidewire with integrated pressure monitoring, aims at improving procedural efficiency and clinical outcomes by allowing multiple steps over the same device without exchange. This device is designed to support the growing minimalist TAVR approach. With the SavvyWire, physicians can expect to implant the percutaneous valve over the same device while obtaining continuous and accurate hemodynamic measurements to assist their diagnosis. The Evolution of TAVR Aortic valve stenosis occurs when the heart's aortic valve narrows, preventing it from opening completely and restricting blood flow from the heart to the main artery (aorta) and then to the rest of the body. The TAVR procedure was initially only indicated for inoperable patients with severe symptomatic aortic stenosis, and later for patients at high surgical risk. Clinical programs such as PARTNER and COREVALVE have since shown better or equivalent clinical outcomes in intermediate and low surgical risk patients. The TAVR procedure is rapidly evolving toward a minimalist approach that advances the procedure and allows patients to leave the hospital earlier, sometimes the same day. The TAVR procedure is growing rapidly globally, driven by the aging population and recent studies that demonstrate its benefits for a broader array of patients. The global TAVR market is currently estimated at over 200,000 procedures and is expected to reach 400,000 in 2027. OpSens focuses mainly in interventional cardiology. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of over 150,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan, and Canada. OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications. Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, and achievements of OpSens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements. Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release. SOURCE OpSens Inc. For further information: Please contact: Louis Laflamme, CPA, CA, Chief Executive Officer, 418.781.0333; Robin Villeneuve, CPA, CA Chief Financial Officer, 418.781.0333 ×

Opsens Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Opsens Rank

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.